Cheonan-si, South Korea

Gi-Hyeok Yang



Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Gi-Hyeok Yang: Pioneering Humanized Antibodies

Introduction: Gi-Hyeok Yang, an esteemed inventor located in Cheonan-si, South Korea, has made significant contributions to the field of biotechnology. With a focus on humanized antibodies, his work is paving the way for advancements in medical therapies. Yang is currently associated with Aprogen Inc., where he continues to push the boundaries of innovation.

Latest Patents: Gi-Hyeok Yang holds a notable patent titled "Humanized antibody and process for preparing same." This patent details a process for producing humanized antibodies, which includes critical steps such as selecting specificity determining residues (SDR) of the complementarity determining regions (CDR) of murine monoclonal antibody heavy chain and light chain variable regions. Moreover, it involves grafting these SDRs to the corresponding amino acid sequences in human antibody variable regions, presenting a groundbreaking method in antibody production.

Career Highlights: Throughout his career, Gi-Hyeok Yang has demonstrated exceptional dedication to research and development in the field of biopharmaceuticals. His innovative approach has not only contributed to the creation of his patent but also showcases his commitment to enhancing therapeutic options through biotechnology and immunology.

Collaborations: At Aprogen Inc., Gi-Hyeok Yang collaborates with talented colleagues such as Hyo Jeong Hong and Cheol-Young Maeng. Together, they combine their expertise to advance the company’s research and create impactful solutions in the sector.

Conclusion: Gi-Hyeok Yang stands out as a prominent figure in the world of innovation, particularly in the development of humanized antibodies. His patent signifies a meaningful step forward in biomedicine, and as he continues to work with skilled professionals at Aprogen Inc., the future of therapeutic innovations looks promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…